Drugs that contain Methylphenidate Hydrochloride

1. List of Adhansia Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 27, 2022
M Jun 28, 2024

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

2. List of Jornay Pm drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder
Mar, 2032

(9 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

3. List of Methylin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880 SPECGX LLC Methylphenidate solution and associated methods of administration and production
Oct, 2024

(1 year, 8 months from now)

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of METHYLIN before it's patent expiration?
More Information on Dosage

4. List of Quillichew Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8202537 NEXTWAVE PHARMS Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8287903 NEXTWAVE PHARMS Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US9545399 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US9295642 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US9844544 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US11103495 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US10857143 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US8999386 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

US11103494 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet
Aug, 2033

(10 years from now)

Market Authorisation Date: 04 December, 2015

Treatment: A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1; A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed; A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

How can I launch a generic of QUILLICHEW ER before it's patent expiration?
More Information on Dosage

5. List of Quillivant Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 NEXTWAVE Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(6 years from now)

US9040083 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8563033 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8956649 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8465765 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8778390 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8287903 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

Market Authorisation Date: 27 September, 2012

Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treatment of a patient by administering the formulation recited in claim 1 or claim 23

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

How can I launch a generic of QUILLIVANT XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic